Glass House Brands (GLAS) Net Income (2020 - 2026)
Glass House Brands' (GLAS) quarterly Net Income came in at -$17.0 million in Q1 2026, down 69.92% year-on-year from -$56.5 million in Q1 2025, and down 9.72% on a QoQ basis from -$15.5 million in Q4 2025.
Glass House Brands (GLAS) Net Income (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Net Income data on file, last reported at -$17.0 million in Q1 2026.
- On a quarterly basis, Net Income fell 69.92% year-over-year to -$17.0 million in Q1 2026; TTM through Mar 2026 was -$35.9 million, a 1031.57% decrease from a year earlier, with the FY2025 full-year figure at -$29.0 million, down 4115.53% from the prior year.
- Net Income for Q1 2026 stood at -$17.0 million, down from -$15.5 million in the prior quarter.
- Over the last five years, Net Income for GLAS reached as high as $127.6 million in Q3 2023 and fell as low as -$18.3 million in Q1 2024.
- Historically, Net Income has averaged $14.5 million across 5 years, with a median of $12.1 million in 2022.
- Across the five-year window, Net Income surged 703.82% in 2023 and slumped 279.93% in 2025, its largest moves.
- Year by year, Net Income stood at $14.4 million in 2022, then soared by 164.38% to $38.1 million in 2023, then tumbled by 108.42% to -$3.2 million in 2024, then slumped by 383.17% to -$15.5 million in 2025, then fell by 9.72% to -$17.0 million in 2026.
- Per Business Quant data, the three most recent Net Income figures were -$17.0 million in Q1 2026, -$15.5 million in Q4 2025, and -$12.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -17.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.01 Mn |
| Dec 31, 2025 | -15.50 Mn |
| Sep 30, 2025 | -12.19 Mn |
| Jun 30, 2025 | 8.74 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Sep 30, 2024 | -3.21 Mn |
| Jun 30, 2024 | 10.04 Mn |
| Mar 31, 2024 | -18.27 Mn |
| Dec 31, 2023 | 38.12 Mn |
| Sep 30, 2023 | 127.59 Mn |
| Jun 30, 2023 | 24.91 Mn |
| Mar 31, 2023 | 34.78 Mn |
| Dec 31, 2022 | 14.42 Mn |
| Sep 30, 2022 | 15.87 Mn |
| Jun 30, 2022 | 14.19 Mn |
| Mar 31, 2022 | 19.83 Mn |
| Dec 31, 2021 | -18.77 Mn |
| Sep 30, 2021 | 7.73 Mn |
| Jun 30, 2021 | 4.72 Mn |
| Mar 31, 2021 | 13.15 Mn |